Decision makers often desire both guidance on the most cost-effective interventions given current knowledge and also the value of collecting additional information to improve the decisions made (i.e., from value of information [VOI] analysis). Unfortunately, VOI analysis remains underused due to the conceptual, mathematical, and computational challenges of implementing Bayesian decision-theoretic approaches in models of sufficient complexity for real-world decision making. In this study, we propose a novel practical approach for conducting VOI analysis using a combination of probabilistic sensitivity analysis, linear regression metamodeling, and unit normal loss integral function-a parametric approach to VOI analysis. We adopt a linear approximation and leverage a fundamental assumption of VOI analysis, which requires that all sources of prior uncertainties be accurately specified. We provide examples of the approach and show that the assumptions we make do not induce substantial bias but greatly reduce the computational time needed to perform VOI analysis. Our approach avoids the need to analytically solve or approximate joint Bayesian updating, requires only one set of probabilistic sensitivity analysis simulations, and can be applied in models with correlated input parameters. D ecision makers often desire both guidance on the most cost-effective interventions given current knowledge and also the value of collecting additional information to improve the decisions made (i.e., from value of information [VOI] analysis). VOI analysis has gained increased interest in clinical trial design and research prioritization. 1-25 However, it remains underused due to the conceptual, mathematical, and computational challenges of implementing Bayesian decision-theoretic concepts in models of sufficient complexity for real-world decision making. [26] [27] [28] A recent review reports a small number of practical applications of VOI in health care settings. 29 This study attributes this small number of applications to the technical and mathematical challenges involved in computing VOI and highlights the importance of developing leaner approaches to conduct VOI analyses.
Decision makers often desire both guidance on the most cost-effective interventions given current knowledge and also the value of collecting additional information to improve the decisions made (i.e., from value of information [VOI] analysis). Unfortunately, VOI analysis remains underused due to the conceptual, mathematical, and computational challenges of implementing Bayesian decision-theoretic approaches in models of sufficient complexity for real-world decision making. In this study, we propose a novel practical approach for conducting VOI analysis using a combination of probabilistic sensitivity analysis, linear regression metamodeling, and unit normal loss integral function-a parametric approach to VOI analysis. We adopt a linear approximation and leverage a fundamental assumption of VOI analysis, which requires that all sources of prior uncertainties be accurately specified. We provide examples of the approach and show that the assumptions we make do not induce substantial bias but greatly reduce the computational time needed to perform VOI analysis. Our approach avoids the need to analytically solve or approximate joint Bayesian updating, requires only one set of probabilistic sensitivity analysis simulations, and can be applied in models with correlated input parameters. Key words: value of information; probabilistic sensitivity analysis; Bayesian statistical methods; simulation methods; cost-benefit analysis. (Med Decis Making 2015; 35: 584-595) D ecision makers often desire both guidance on the most cost-effective interventions given current knowledge and also the value of collecting additional information to improve the decisions made (i.e., from value of information [VOI] analysis). VOI analysis has gained increased interest in clinical trial design and research prioritization. However, it remains underused due to the conceptual, mathematical, and computational challenges of implementing Bayesian decision-theoretic concepts in models of sufficient complexity for real-world decision making. [26] [27] [28] A recent review reports a small number of practical applications of VOI in health care settings. 29 This study attributes this small number of applications to the technical and mathematical challenges involved in computing VOI and highlights the importance of developing leaner approaches to conduct VOI analyses.
The most practical form of VOI analyses involves quantifying the amount of information an actual empirical study could generate. While VOI analyses can provide an upper bound on the value of conducting additional studies (i.e., expected value of perfect information on all parameters [EVPI] or expected value of partial perfect information on a set of parameters [EVPPI]), the expected value of sample information for a study of size (n) (EVSI) and its analog for sample information on some parameters (EVPSI) are clearly more useful for informing actual decisions to collect further information. 26 Current methods for performing EVPSI are often challenging for real-world modeling problems, necessitating further methodological development, and are yet to be incorporated into the standard statistical and mathematical software packages (e.g., Tree-Age; TreeAge Software, Inc., Williamstown, MA). For example, the 2-level Monte-Carlo simulation 30 (2MCS) approach, which can be considered the gold-standard for computing EVPSI, consists of an outer and inner expectation. The outer expectation is computed through an outer loop to generate a large number of experimental data sets from the prior distributions. The inner loop samples from the posterior distribution generated from these data sets. However, if a conjugate prior does not exist for the likelihood function, then the posterior distribution must be obtained using techniques such as the Markov chain Monte Carlo (MCMC). In addition to the computational demand, the 2MCS approach may require Bayesian updating of correlated parameters and calculating joint posterior distributions, which are extremely difficult except in special cases. Thus, for a single parameter and with a sufficient number of model runs, this approach guarantees a precise estimate of EVPSI, but it can be extremely difficult to compute EVPSI, especially for multiple correlated parameters.
Several shortcut techniques have been proposed to reduce the computational burden of the 2MCS approach. Some of these approaches are designed for specific applications. For example, Ades et al. 26 demonstrate an analytic approach to measure the EVPSI for parameter types common in clinical trials, such as rates and odds ratios; Welton et al. 31 compute EVPSI for cluster randomized multiarm trials with binary outcomes; and Brennan and Kharroubi 32 illustrate a technique to compute EVPSI for survival data. Other proposed approximation techniques include Laplace approximation 33 and nonparametric regression 34 approaches to efficiently compute EVPSI. Most of these shortcut techniques offer significant reduction of the computation burden of the 2MCS approach by avoiding the inner expectation and the need for MCMC analysis. However, these approaches generally require additional development efforts, sometimes ignore correlations among various model parameters, and are often limited to calculating EVPSI for a single parameter at a time.
We describe a novel framework to compute EVPPI and EVPSI using the unit normal loss integral (UNLI) function and linear regression metamodeling (LRM). The UNLI is a parametric function for computing VOI from a model's outcome. This approach was originally proposed by Raiffa and Schlaifer [35] [36] [37] more than 50 years ago. Since then many researchers 7, 16, [38] [39] [40] have adopted this approach to compute EVPI, EVSI, and, to some extent, EVPPI. In this study, we extend the UNLI function to compute EVPPI and EVPSI using LRM, which involves regressing the model's outcome on the input parameter values using a probabilistic sensitivity analysis (PSA) data set. 41 In addition, we demonstrate the importance of correlation among model parameters in VOI analysis and the flexibility of our approach in allowing the model parameters to be correlated. We highlight the assumptions of our approach and illustrate why our approach may still be appropriate for most health care applications despite these assumptions.
METHODS

Incremental Net Benefit
Expected utility maximization involves choosing the strategy that has the highest expected net benefit. We use incremental net benefit (INB) as our measure of cost-effectiveness instead of the cost-effectiveness ratio because it has attractive statistical properties in our application. [42] [43] [44] INB measures the incremental net benefit of adopting the optimal strategy (t Ã ) relative to an alternative (t Ã ) based on the current evidence. An intervention's net benefit (B), when expressed in a monetary value, measures the savings from an intervention (t) relative to a marginally costeffective intervention at a specified willingness-topay threshold.
Approximating Measures of VOI
To compute VOI measures, we first obtain the INB distribution via probabilistic sensitivity analysis (PSA). We can then apply the UNLI to compute EVPI and EVSI 35, 36 using the INB distribution. Finally, we extend the UNLI approach to calculate EVPPI and EVPSI using linear regression metamodeling (LRM). 41 EVPI EVPI can be computed from the expected opportunity loss due to choosing t Ã over t Ã based on the current evidence. This loss (L) can be expressed as
where f is the density function of INB. The relationship of this opportunity loss to INB's distribution is further illustrated in Appendix A (available online). When f is normally distributed, L can be computed from the UNLI function, such as
where m and s 2 are the mean and variance of the INB, respectively, and F is the cumulative density function of the standard normal distribution (for more detail, please refer to Raiffa and Schlaifer 35 and Raiffa 36 ). Box 1 outlines the steps of computing EVPI using PSA and UNLI. First, obtain INB's distribution using PSA results. 45, 46 We can think of the resulting distribution as the prior distribution of INB because it reflects the combined uncertainty from all the parameters in the model prior to conducting new research. EVPI is computed from the mean and variance of the INB distribution using the UNLI function (equation (2) ). Note that we take the negative of the UNLI to express EVPI as a value instead of a loss.
EVSI
Box 2 outlines the steps of calculating EVSI using the UNLI approach. 35, 36 This approach is similar to calculating EVPI. However, unlike EVPI, which uses the prior distribution of INB, EVSI uses the preposterior distribution 35, 36 of the INB. The preposterior distribution defines the distribution of the posterior mean INB, which is derived from the INB's prior distribution and additional experimental ''data'' that are also simulated from the prior. Thus, the preposterior distribution defines the prior distribution of the posterior mean INB before collecting actual data, hence the name preposterior.
First, we compute the variance of the preposterior distribution of INB. When the prior distribution of INB is normally distributed, the preposterior variance of INB can be expressed as a fraction of the prior variance, such that s 2 1 5 s 2 0 v, where v is the variance fraction equal to n= n 1 n 0 ð Þ, n is the additional sample size, and n 0 is the prior sample size. n 0 can be arbitrary 35 or estimated from the prior distribution (e.g., if a parameter is distributed as Beta(a, b), it can be shown 47 that n 0 5 a 1 b). Thus, if we assume that no additional sample is to be collected (n 5 0), the posterior INB will always be equal to the prior INB, and the mean posterior INB is certain to be equal to the mean prior INB, which is known. Thus, there is no uncertainty about the posterior mean INB (s 2 1 5 0), and there is no value for conducting additional research (EVSI = 0). However, if we imagine an experiment in which we take an infinitely large sample from each value of the prior (n 5 '), then for each prior sample, the posterior mean INB is certain to be equal to this sampled value of the prior INB. Repeating this exercise many times produces the posterior distribution of the mean INB (i.e., preposterior INB distribution), which will exactly follow that of Box 1 EVPI Algorithm
1.1: Probabilistic sensitivity analysis (PSA):
Assign appropriate distributions for the uncertain input parameters to reflect their uncertainties.
Sample m values from each parameter, and obtain a matrix X of input parameter values, where x ij represents the ith value (i 5 1 . . . m) of the jth parameter.
Determine the optimal strategy (t Ã ) that maximizes the net benefit (B) over all parameter uncertainties max t E X B t; X ð Þ. For each set of parameter values (x i ), compute INB i as the difference between the net benefit of the optimal strategy (t Ã ) less that of the alternative
Compute m 0 and s 2 0 as the mean and variance of the incremental net benefit's (INB's) prior distribution.
1.2: Unit normal loss integral (UNLI)
Use equation (2) to compute the expected value of perfect information on all parameters (EVPI), such as:
Box 2 EVSI Algorithm and EVSI equals EVPI.
EVPPI
Boxes 1 and 2 review how to compute EVPI and EVSI using the UNLI function. Next, we focus on the main contribution of the current study, which extends the UNLI function to computing EVPPI and EVPSI using the LRM approach.
Box 3 summarizes the steps to compute EVPPI, which are very similar to calculating EVPI. Unlike EVPI, which reflects prior uncertainties from all parameters in the model, EVPPI involves the uncertainty in the prior INB explained by a subset of parameters of interest. We denote this subset of parameters by X I and the mean and variance of the distribution of INBjX I bym 0 ands 2 0 , respectively. We use the LRM approach to computem 0 ands 2 0 . LRM involves regressing INB on the model inputs. Thus, LRM is the application of classical regression analysis after simulation analysis, hence the name metamodeling. Metamodeling is widely used in engineering and physics but remains underused in health care applictions. 41, 48 By treating the INB as the dependent variable and the model input parameters of interest (X I ) as the independent variables, the resulting regression coefficients define the relationship between X I and INB. We use these regression coefficients to compute EVPPI and EVPSI.
In EVPPI (and also in the EVPSI calculation described below), we adopt 2 approximations: 1) a normal approximation of X I and 2) a linear approximation of the relationship between X I and INB. It is important to note that unlike EVPI and EVSI, which assumes that the INB is normally distributed, when applying LRM, the INB does not need to be normally distributed as long as the prior or the preposterior distributions of X I (for EVPPI or EVPSI, respectively) are normally distributed and their relationships with INB are approximately linear. 40 In addition, as we shall discuss later, the normality of X I and the reliability of all VOI analyses are closely related per the central limit theorem.
In the algorithm above, we use X I instead of the full set of parameters (X 5 X I ; X C f g) to account for the potential correlations between the X I and X C parameters in the model. If such correlations exist, any additional information on X I will affect our prior belief about X C . Since we are only interested in X I , we want this additional information to be captured by the regression coefficients of X I . However, regressing INB on the full set of parameters (X) instead of X I results in the regression coefficients of X C capturing this additional effect, which can bias the EVPPI and EVPSI values since the regression coefficients of X C are not of interest and do not enter in the calculation ofs 2 0 . As a result,s 2 0 can be underestimated or overestimated depending on the nature of the existing correlation and the direction of the regression coefficients. (Please refer to online Appendix B for further detail.)
EVPSI
Following the logic used to calculate EVSI and EVPPI, EVPSI can be computed from the preposterior variance for INB explained by X I (Box 4) . We denote this variance bys 2 1 . To obtains 2 1 , we calculates 2 0 for X I using LRM. Then we use the variance fraction v to compute the preposterior variance. If the prior If n 0 and n are the same for all X I , then computẽ s 2 1 5 vs 2 0 . Otherwise, in a heterogeneous design, compute a vector of variance fractions (v), such as v j 5 n j = n j 1 n 0j À Á , where v j represents the variance fraction for x j , x j 2 X I , and n j and n 0j represent the sample sizes for the prior and additional samples for x j , respectively. Then, computẽ evidence (n 0 ) is the same across all X I and the new study contributes equal additional samples (n) to these parameters, thens 2 1 5 vs 2 0 . However, if the n 0 varies among the parameters or if the proposed study adopts a heterogeneous design in which different samples contribute different information to the model parameters, then the prior variance must be adjusted by decomposings 2 0 and applying the appropriate variance fractions on the parameter level.
Thus, the computation for the various VOI analyses depends on the mean and variance of the INB, as summarized in Table 1 .
CASE STUDIES
We illustrate our approach using 2 examples: a standard decision tree and a Markov model.
Example 1: Standard Decision Tree
The first example involves a decision model published by Ades et al. 26 (Appendix C, available online). This model compares a new intervention to the standard of care in preventing a hypothetical critical condition. The new treatment reduces the risk of the critical event, but it may cause side effects. There are 11 parameters in the model, 4 of which are uncertain and are represented by probabilistic distributions.
Correlated parameters may represent a limitation of computing EVPSI. 26 However, in practical applications, uncertainties of model parameters are rarely independent. These correlations may reflect subjective uncertainty about joint parameter distributions or may be induced as a result of statistical analyses. 26, 49 We introduce correlation between the treatment's side effects (p SE ) and the risk of the critical events (OR) using a previously developed sorting algorithm. 50 We vary the correlation between these parameters from À1 to 1 1 and examine the resulting EVPSI of these 2 parameters combined for various study sample sizes.
Example 2: Markov Model
The second example involves a Markov model, which defines a more complex relationship between INB and the model parameters compared with the first example. This model involves computing the most cost-effective alternative for treating a 50-year-old cohort of newly diagnosed cancer patients (Appendix D, available online). The treatment choices are either to receive chemotherapy or perform a surgical resection of the tumor. There are 3 Markov health states in the model (cancer free, cancer, and dead). If cured, the quality of life increases from 0.8 to 1, but the probability of cure depends on the intervention chosen. If cured, the patients are assumed to remain cancer free for the remainder of their lives. Annual mortality rates are calculated from the US life tables and an additional cancer-specific mortality, which is uncertain. In addition, we use a 1-year cycle length, a lifetime horizon, and a discounting rate of 5% annually for the benefits and costs.
RESULTS
Example 1: Standard Decision Tree
Our implementation of the Ades model produces results and estimates of VOI that are similar to the analytical method proposed by Ades et al. 26 ( Table 2 ). The EVPI, probability of the new treatment not being optimal, and the EVPPI for the listed parameters are comparable between both methods. The relative contribution of various parameters to decision uncertainty and hence to EVPPI is also preserved. Uncertainty regarding the probability of side effects is the most important followed by the odds ratio of the critical event and the quality of life after the critical event. There are slight variations in the estimated EVPPI using the LRM compared with the analytic approach, which may be due to a combination of violating the normality and linearity assumptions.
Our estimates of EVPSI also compare favorably with the analytic approach. The EVPSI is shown for p SE and Q E (Figure 1 ) and the combination of p SE , Q E , and LOR (Figure 2 ). Our exploration of EVPSI's asymptotic properties follows the theoretical predictions. Again, our approach slightly overestimates the EVPSI for the quality of life after the critical event (Q E ) and underestimates the EVPSI of the odds ratio of the event for the treatment (OR); however, the sample sizes are relatively small (n 0 = 12). Larger sample sizes may increase the normality of the preposterior distribution and the accuracy of our approach.
Next we demonstrate the flexibility of our approach to incorporate correlations among model parameters (Figure 3 ). Varying correlation between the treatment's probability of causing side effects (p SE ) and the odds ratio of the critical event (OR) from À1 to 1 1 results in a 6-fold increase in EVPPI from $2000 to $12,000, indicating the potential impact of correlation between model parameters on their EVPPI and EVPSI.
Example 2: Markov Model
Although the probability of failing chemotherapy (pFailChemo) is expected to have a nonlinear relationship with INB, we found a nearly linear relationship (R 2 = 98.3%), indicating that linear approximation may be appropriate in this model. We chose to demonstrate the VOI analyses and compare the results of our LRM approach with the 2MCS approach. We conducted the 2MCS computations using a server with 128 gigabytes of memory and 12 processing cores that were used simultaneously in parallel to increase the speed of the computations. We used a single processing core to conduct LRM.
The EVPPI for the probability of failing chemotherapy is $18,050 and $17,800 using the 2MCS and the LRM methods, respectively. Figure 4 compares the performance of the LRM and the 2MCS approaches.
The LRM computation took only 1.6 ms on a single core compared to more than 25 minutes for the 2MCS approach using 12 threads in parallel, a 20,000-fold gain in computation time compared with the 2MCS approach. It is important to mention that this may underestimate the potential gain in the computation time of the LRM approach relative to the 2MCS because we used a beta prior distribution and a binomial data likelihood function. This conjugate prior/ likelihood combination has resulted in a significant gain in the computation time compared with situations in which a conjugate prior may not exist.
DISCUSSION
We describe a practical and feasible method to estimate EVPSI, which enables such calculations in models whose complexity would have previously rendered methods to estimate EVPSI intractable. Our method combines standard tools and concepts, including the UNLI, developed by Raiffa and Schlaifer 35 for EVPI and EVSI; PSA, which is now performed for most models; and linear regression metamodeling, which only requires standard statistical software and the outputs of the PSA. LRM allows us to extend Raiffa and Schlaifer's past application to EVPPI and EVPSI. We illustrate our approach with a case study of a simple decision tree and a more complex Markov model.
The LRM approach is extremely efficient, flexible, and easy to implement. This approach consists of a set of simple equations using a single data set of PSA results. (In online Appendix F, we provide a sample code to compute EVPSI using Microsoft Excel and R.) This approach resulted in more than a 20,000-fold decrease in computation time compared with the 2MCS approach using a Markov model. Higher performance improvements are expected in more complex models and for nonconjugate prior/likelihood combinations, which may require additional MCMC simulations.
In addition, the LRM approach can be easily extended to calculate the EVPPI and EVPSI for a combination of multiple parameters, when correlations exist among the parameters of interest, among the complementary set of parameters, and between these two sets of parameters. Furthermore, this approach can also be used for heterogeneous trial designs that involve various sample allocations to the individual parameters. Figure 1 Comparing the results of the LRM and analytic approaches from example 1. The EVPSI is shown for the probability of the new treatment causing side effects (p SE ) and the quality of life after the event (Q E ). LRM, linear regression metamodeling; EVPSI, expected value of partial sample information.
Our approach has several limitations. First, we adopt a normal approximation of the prior and preposterior distributions for the parameters of interest in EVPPI and EVPSI computations, respectively. This approximation can bias the results if these parameters are ''severely'' nonnormal. However, normal approximation as shown by Raiffa and Schlaifer 35 and Schlaifer 37 is an excellent approximation to a large number of real distributions of practical importance. If the parameter distribution is based on bootstrapping the sample mean or published estimates of a sufficiently large sample size, then a normal approximation of the parameter's estimate is perhaps sufficient per the central limit theorem. In some cases, however, the parameter's estimates may not be normally distributed, especially in the case of subjective estimation of uncertainty, limited prior evidence (e.g., n 0 10), or when meta-analyzing treatment effects from heterogeneous and inconsistent data sources. [51] [52] [53] [54] [55] [56] [57] Most of these cases are perhaps instances of less accurate specification of the prior uncertainties, which may compromise the reliability of all VOI analyses because these analyses are inherently dependent on how ''accurately'' these prior uncertainties are specified.
Second, our approach may be limited to models in which the relationship between INB and X I is approximately linear. Although some decision models are generally nonlinear (e.g., Markov models), we illustrated with a Markov model that this relationship can be well approximated with a linear relationship. Because we lack empirical evidence that quantifies the degree of nonlinearity in various model types, the level of linearity should be determined on case-by-case bases. In fact, many decision models used in health care applications can be approximated well with an LRM. For example, Coyle and Oakley 40 show that regressing the INB on the model parameters of a Markov model produces an R 2 of 0.985. In addition, Tappenden et al. 58 find a strong linear relationship (R 2 = 0.93) between the model parameters and the resulting net benefit values in a complex model. This high degree of linearity can be explained by several factors: 1) INB may be locally linear because its functional form is assessed only over a parameter's uncertainty range ( Figure 5A and 3) discounting future rewards may also contribute to increased linearity of INB. This is because each benefit function is the aggregation of future rewards weighted by the probability of being in a Markov state. Although the functional form of these probabilities increases in nonlinearity in future cycles, they become rapidly less impactful when the future rewards are discounted. In all cases, we recommend that a model's linearity should be assessed visually and with a goodness-of-fit statistic (e.g., R 2 ). Both case studies in this article reveal high degrees of linearity (R 2 of 94.7% and 98.3% for case studies 1 and 2, respectively). Further research is needed to assess the performance of our approach on less linear and more complex models.
Higher order polynomials (e.g., x 2 and x 3 ) terms can improve the overall fit of the LRM, but care must be given when using these higher order terms in LRM with UNLI. For example, if a parameter x is normally distributed, then the UNLI function can be applied because y is normally distributed in y 5 b 0 1 b 1 x. In contrast, even if y 5 b 0 1 b 1 x 1 b 2 x 2 provides a better fit, it may not increase the overall accuracy of the value of information calculation because x 2 may not be normally distributed. Further research is needed to extend the LRM approach using polynomial regression analysis.
Third, an important limitation of the UNLI function is that it is designed for models that involve two strategies only. We propose two alternatives for models that involve 3 or more strategies (multipleaction models): 1) the overall INB can be defined as Figure 3 The impact of correlation between the probability of side effects (p SE ) and the odds ratio of the critical event (OR) on the EVPPI and EVPSI of these two parameters combined in example 1. The EVPSI is shown for three sample sizes n = 1, 20, and 200. Correlation has a significant impact on EVPPI and EVPSI; this impact is proportional to the sample size. EVPPI, expected value of partial perfect information; EVPSI, expected value of partial sample information. may bias the VOI analysis because the parameter of interest may have a stronger correlation with a third strategy that is not captured by this definition of the INB. 2) If the calculated INB is not approximately normal, then the UNLI method can still be applied for a single parameter, but it requires additional complexity. First, INB must be computed for each strategy relative to the optimal strategy, such that INB t 5 B t Ã ; X ð ÞÀB t; X ð Þ, and then the UNLI function can be applied for each INB t over each strategy's (t) dominance region with respect to the parameter of interest. Next, the algorithms above are applied for all INB t in each region. The overall value of information is computed as the aggregate of the individual opportunity losses in each of these regions. (Online Appendix E generalizes the UNLI technique to models that involve 3 or more strategies. Further research is needed to extend this approach to multiple parameters.)
Finally, while multicollinearity is a potential limitation of linear regression analysis, it may not be as important in metamodeling. Multicollinearity can theoretically increase the standard error of the LRM coefficients, thus affecting the stability of these coefficients when the model parameters are highly correlated. In practice, multicollinearity is less of an issue due to the vast improvement in computational precision. We found no evidence of multicollinearity (results are not shown) in LRM except when the parameters were in near-perfect correlation. Clearly, perfect correlation does not apply to decision modeling because if 2 parameters are perfectly correlated, only one will be necessary in the model.
CONCLUSION
EVPSI has many potential applications in health care, but it is one of the most challenging measures to quantify both methodologically and computationally. We propose an approximation technique to conduct VOI analysis. Our approach performs best if 1) the preposterior distribution of the model parameters of interest is approximately normally distributed, an assumption strongly tied to the reliability of the VOI analysis, and 2) the relationship of the parameters of interest and the INB is approximately linear, which is common in many simulation models in health care, including Markov models. Because our approach is simple, flexible, and extremely efficient, we propose it as an additional tool for analysts wishing to conduct VOI analyses.
